Work Files Saved Searches
   My Account                                                  Search:   Quick/Number   Boolean   Advanced   Derwent    Help   


 The Delphion Integrated View
  Buy Now:   Buy PDF- 28pp  PDF  |   File History  |   Other choices   
  Tools:  Citation Link  |  Add to Work File:    
  View:  Expand Details   |  INPADOC   |  Jump to: 
  Go to:  Derwent  
 Email this to a friend  Email this to a friend 
       
Title: US6268473: α-conotoxin peptides
[ Derwent Title ]
>> View Certificate of Correction for this publication

Country: US United States of America

View Images High
Resolution

 Low
 Resolution

 
28 pages

 
Inventor: Olivera, Baldomero M.; Salt Lake City, UT
Layer, Richard T.; Sandy, UT
Watkins, Maren; Salt Lake City, UT
Hillyard, David R.; Salt Lake City, UT
McIntosh, J. Michael; Salt Lake City, UT
Schoenfeld, Robert; Sacramento, CA
Jones, Robert M.; Salt Lake City, UT

Assignee: University of Utah Research Foundation, Salt Lake City, UT
Cognetix, Inc., Salt Lake City, UT
other patents from UNIVERSITY OF UTAH RESEARCH FOUNDATION (600050) (approx. 286)
 News, Profiles, Stocks and More about this company

Published / Filed: 2001-07-31 / 2000-01-21

Application Number: US2000000488799
IPC Code: Advanced: C07K 14/435; A61K 38/00;
Core: more...
IPC-7: A61K 38/10; A61K 38/17; C07K 7/08; C07K 14/00; C07K 14/435;

ECLA Code: C07K14/435A;

U.S. Class: Current: 530/325; 435/069.1; 435/069.7; 435/320.1; 530/324; 530/328; 530/350;
Original: 530/325; 530/325; 530/324; 530/328; 530/350; 435/069.1; 435/069.7; 435/320.1;

Field of Search: 435/69.7,69.1,320.1 530/350,325,328

Government Interest:     This invention was made with Government support under Grant No. PO1 GM48677 awarded by the National Institute of General Medical Sciences, National Institutes of Health, Bethesda, Md. The United States Government has certain rights in the invention.

Priority Number:
2000-01-21  US2000000488799
1999-01-22  US1999000116881P
1999-01-22  US1999000116882P

Abstract:     The invention relates to relatively short peptides (termed alpha-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The alpha-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.

Attorney, Agent or Firm: Rothwell, Figg, Ernst & Manbeck, pc ;

Primary / Asst. Examiners: Carlson, Karen Cochrane; Robinson, Patricia
Maintenance Status: CC Certificate of Correction issued
View Certificate of Correction

INPADOC Legal Status: Show legal status actions          Buy Now: Family Legal Status Report

Parent Case:

CROSS-REFERENCE TO RELATED APPLICATIONS
    The present application is related to U.S. provisional patent applications Serial Nos. 60/116,881 and 60/116,882, both filed on Jan. 22, 1999 and both incorporated herein by reference.

Designated Country: AE AL AM AP AT AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EA EE EP ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG 

Family: Show 15 known family members
First Claim:
Show all 33 claims		 What is claimed is:     1. A substantially pure α-conotoxin peptide seleceted from the group consisting of:
  • Xaa1 -Cys-Cys-Asn-Xaa2 -Ala-Cys-Gly-Arg-His-Xaa3 -Ser-Cys-Xaa4 -Gly (SEQ ID NO:3);
  • Asn-Gly-Arg-Cys-Cys-His-Xaa2 -Ala-Cys-Gly-Xaa4 -His-Phe-Ser-Cys (SEQ ID NO:4);
  • Gly-Arg-Gly-Arg-Cys-Cys-His-Xaa2 -Ala-Cys-Gly-Xaa2 -Asn-Xaa3 -Ser-Cys (SEQ ID NO:5);
  • Cys-Cys-His-Xaa2 -Ala-Cys-Gly-Arg-Xaa4 -Xaa3 -Asn-Cys (SEQ ID NO:6);
  • Cys-Cys-Cys-Asn-Xaa2 -Ala-Cys-Gly-Xaa2 -Asn-Xaa3 -Gly-Cys-Gly-Thr-Ser-Cys-Ser-Arg-Xaa2 -Ser-Xaa1 -Xaa2 -Arg-Arg (SEQ ID NO:7);
  • Asn-Gly-His-Cys-Cys-His-Xaa2 -Ala-Cys-Gly-Gly-Xaa4 -Xaa3 -Val-Xaa4 -Cys (SEQ ID NO:8);
  • Asn-Gly-Arg-Cys-Cys-His-Xaa2 -Ala-Cys-Gly-Gly-Xaa4 -Xaa3 -Val-Xaa4 -Cys (SEQ ID NO:9);
  • Asn-Gly-Arg-Cys-Cys-His-Xaa2 -Ala-Cys-Gly-Xaa4 -His-Phe-Ile-Cys (SEQ ID NO:10);
  • Asn-Gly-Arg-Cys-Cys-His-Xaa2 -Ala-Cys-Gly-Xaa4 -His-Phe-Ser-Cys (SEQ ID NO:11);
  • Asn-Gly-Arg-Cys-Cys-His-Xaa2 -Ser-Cys-Gly-Arg-Xaa4 -Xaa3 -Asn-Cys (SEQ ID NO:12);
  • Asn-Gly-Arg-Cys-Cys-His-Xaa2 -Ala-Cys-Ala-Arg-Xaa4 -Xaa3 -Asn-Cys (SEQ ID NO:13);
  • Asn-Xaa1 -Arg-Cys-Cys-His-Xaa2 -Ala-Cys-Ala-Arg-Xaa4 -Xaa3 -Asn-Cys (SEQ ID NO:14);
  • Asp-Gly-Arg-Cys-Cys-His-Xaa2 -Ala-Cys-Gly-Gln-Asn-Xaa3 -Ser-Cys (SEQ ID NO:15);
  • Asp-Gly-Arg-Cys-Cys-His-Xaa2 -Ala-Cys-Ala-Xaa4 -His-Phe-Asn-Cys (SEQ ID NO:16);
  • Asn-Gly-Arg-Cys-Cys-His-Xaa2 -Ala-Cys-Ala-Xaa4 -Asn-Xaa3 -Ser-Cys (SEQ ID NO:17);
  • Asn-Gly-Arg-Cys-Cys-His-Xaa2 -Ala-Cys-Ala-Arg-Xaa4 -Xaa3 -Ser-Cys (SEQ ID NO:18);
  • Xaa5 -Cys-Cys-Asn-Xaa2 -Ala-Cys-Gly-Xaa2 -Xaa4 -Xaa3 -Ser-Cys (SEQ ID NO:19);
  • Xaa5 -Cys-Cys-His-Xaa2 -Ala-Cys-Gly-Xaa4 -Xaa4 -Xaa3 -Asn-Cys (SEQ ID NO:20);
  • Ser-Gly-Arg-Cys-Cys-His-Xaa2 -Ala-Cys-Gly-Arg-Xaa4 -Xaa3 -Asn-Cys (SEQ ID NO:21);
  • Arg-Asp-Xaa2 -Cys-Cys-Ser-Asn-Xaa2 -Val-Cys-Thr-Val-His-Asn-Xaa2 -Gln-Ile-Cys (SEQ ID NO:22);
  • Arg-Ala-Cys-Cys-Ser-Xaa3 -Xaa2 -Xaa2 -Cys-Asn-Val-Asn-Xaa3 -Xaa2 -Xaa1 -Ile-Cys (SEQ ID NO:23);
  • Gly-Gly-Cys-Cys-Ser-Xaa3 -Xaa2 -Xaa2 -Cys-Asn-Val-Ser-Xaa3 -Xaa2 -Xaa1 -Ile-Cys (SEQ ID NO:24);
  • Ser-Leu-Leu-Cys-Cys-Thr-Ile-Xaa2 -Ser-Cys-Xaa4 -Ala-Ser-Xaa3 -Xaa2 -Asp-Ile-Cys (SEQ ID NO:27),
  • wherein Xaa1 is Glu or γ-carboxy-glutamate (Gla); Xaa2 is Pro or hydroxy-Pro; Xaa3 is Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr or nitro-Tyr; Xaa4 is Lys, N-methyl-Lys, N,N-dimethyl-Lys or N,N,N-trimethyl-Lys; Xaa5 is Gln or pyro-Glu; and the C-terminus contains a carboxyl or amide group, the polypeptide being substantially free of other peptides.
    •


Background / Summary: Show background / summary

Drawing Descriptions: Show drawing descriptions

Description: Show description

       
U.S. References: Go to Result Set: All U.S. references   |  No patents reference this one   |   Backward references (5)   |   Citation Link

Buy
PDF		 Patent  Pub.Date  Inventor Assignee   Title
Buy PDF- 10pp US4447356  1984-05 Olivera et al.   Conotoxins
Buy PDF- 15pp US5231011  1993-07 Hillyard et al.  University of Utah Segregated folding determinants for small disulfide-rich peptides
Buy PDF- 15pp US5432155  1995-07 Olivera et al.  The Salk Institute For Biological Studies Conotoxins I
Buy PDF- 32pp US5514774  1996-05 Olivera et al.  University of Utah Research Foundation Conotoxin peptides
Buy PDF- 7pp US5969096  1999-10 Shon et al.  The Salk Institute for Biological Studies Conotoxin peptides
       
Foreign References:
Buy
PDF		 Publication Date IPC Code Assignee   Title
Buy PDF EP0593450 1994-04  A61K 37/02 NEUREX CORPORATION COMPOSITIONS FOR TREATING ISCHEMIA-RELATED NEURONAL DAMAGE 
Buy PDF EP0625162 1994-11  A61K 38/00 NEUREX CORPORATION METHODS OF PRODUCING ANALGESIA AND ENHANCING OPIATE ANALGESIA 
Buy PDF- 75pp WO9107980 1991-06  A61K 37/02 NEUREX CORPORATION COMPOSITIONS FOR TREATING ISCHEMIA-RELATED NEURONAL DAMAGE 
Buy PDF- 105pp WO9310145 1993-05  A61K 38/00 BITNER, Robert, S. COMPOSITIONS FOR DELAYED TREATMENT OF ISCHEMIA-RELATED NEURONAL DAMAGE 
Buy PDF- 92pp WO9313128 1993-07  A61K 38/00 GOHIL, Kishor, Chandra METHODS OF PRODUCING ANALGESIA AND ENHANCING OPIATE ANALGESIA 
Buy PDF- 81pp WO9954350 1999-10  C07K 14/435 NIELSEN, KATHERINE, JUSTINE NOVEL OMEGA CONOTOXIN PEPTIDES 
  WO0000WO0015654 2000-03       


Other Abstract Info: CHEMABS 133(10)131093V DERABS C2000-499215

Other References:
  • Olivera et al. (1985). Science 230:1338-1343. (6 pages) Cited by 25 patents
  • Olivera et al. (1990). Science 249:257-263. (7 pages) Cited by 36 patents
  • Myers et al. (1993). Chem. Rev. 93:1923-1936. (14 pages) Cited by 14 patents [ISI abstract]
  • Blount et al. (1992). Toxicon. 30(8):835-842. (8 pages) Cited by 3 patents [ISI abstract]
  • Gray et al. (1981). J. Biol. Chem. 256(10):4734-4740. (7 pages) Cited by 14 patents
  • Hashimoto et al. (1985). Eur. J. Pharmacol. 118:355-354. (9 pages)
  • Marshall et al. (1990). Toxicon. 28(2):231-234. (4 pages) Cited by 3 patents
  • McManus et al. (1985). J. Neurosci. 5(1):110-116. (7 pages) Cited by 3 patents
  • McManus et al. (1981). Neurosci. Letts. 24:57-62. (6 pages) Cited by 3 patents
  • Smythies (1981). Medical Hypotheses 7:1457-1460. (4 pages) Cited by 3 patents
  • Bevan (1997). J. Clin. Anesthesia 9:365, 375, 385, 395.
  • Bowman (1997). Asia Pacific J. Pharmacol. 12:57-64.
  • Bren et al. (2000). J. Biol. Chem.275(17):12692-12700. (9 pages) Cited by 3 patents [ISI abstract]
  • Jacobsen et al. (1999). Biochem. 38:13310-13315. (6 pages) Cited by 3 patents [ISI abstract]
  • Hann et al. (1994). Biochem. 33:14058-14063. (6 pages) Cited by 3 patents [ISI abstract]
  • Groebe et al. (1997). Biochem. 36:6469-6474. (6 pages) Cited by 3 patents [ISI abstract]
  • Groebe et al. (1995). Mol. Pharmacol. 48:105-111. (7 pages) Cited by 11 patents [ISI abstract]
  • Hann et al. (1997). Biochem. 36:9051-9056. (6 pages) Cited by 3 patents [ISI abstract]
  • Almquist et al. (1989). Int. J. Peptide Protein Res. 34:455-462. (8 pages) Cited by 4 patents
  • McIntosh et al. (1982). Arch. Biochem. & Biophys. 218(1):329-334. (6 pages) Cited by 8 patents
  • Richard M. Hann, et al., "The α-Conotoxins GI and MI Distinguish between the Nicotinic Acetylcholine Receptor Agonist Sites while SI Does Not", Biochemistry vol. 33, No. 47, 1994, pp. 14058-14063. (6 pages) Cited by 3 patents [ISI abstract]
  • Duncan R. Groebe, et al., "Determinants Involved in the Affinity of α-Conotoxins GI and SI for the Muscle Subtytpe of Nicotinic Acetylcholine Receptors", Biochemistry, vol. 36, No. 21, 1997, pp. 6469-6474. (6 pages) Cited by 3 patents [ISI abstract]
  • Duncan R. Groebe, et al., "α-Conotoxins Selectively Inhibit One of the Two Acetycholine Binding Sites of Nicotinic Receptors", Molecular Pharmacology, vol. 48, 1995, pp. 105-111. (7 pages) Cited by 11 patents [ISI abstract]
  • Ronald G. Almquist, et al., "Paralytic activity of des-Glu1)conotoxin GI analogs in the mouse diaphragm", Int. J. Peptide Protein Res., vol. 34, 1989, pp. 455-462. (8 pages) Cited by 4 patents
  • Richard M. Hann, et al., "The 9-Arginine Residue of α-Conotoxin GI is Responsible for Its Selective High Affinity for the αγ Agonist Site on the Electric Organ Acetylcholine Receptor", Biochemistry, vol. 36, No. 29, 1997, pp. 9051-9056. (6 pages) Cited by 3 patents [ISI abstract]
  • Richard B. Jacobsen, et al., "Critical Residues Influence the Affinity and Selectivity of α-Conotoxin MI for Nicotinic Acetylcholine Receptors", Biochemistry, vol. 38, No. 40, 1999, pp. 13310-13315. (6 pages) Cited by 3 patents [ISI abstract]
  • Nina Bren, et al., "Hydrophobic Pairwise Interactions Stabilize α-Conotoxin Ml in the Muscle Acetylcholine Receptor Binding Site", The Journal of Biological Chemistry, vol. 275, No. 17, Apr. 28, 2000, pp. 12692-12700. (9 pages) Cited by 3 patents [ISI abstract]
  • Letter to the Editor, "Development of New Neuromuscular Blocking Drugs", Asia Pacific Journal of Pharmacology, vol. 12, 1997, pp. 57-64.
  • David R. Bevan, et al. "Neuromuscular Blocking Drugs: Onset and Intubation", Journal of Clinical Anesthesia, vol. 9, Sep. 1997, pp. 383-396.
  • M. McIntosh, et al., "Isolation and Structure of a Peptide Toxin from the Marin Snal Conus magus", Archives of Biochemistry and Biophysics, vol. 218, No. 1, Oct. 1, 1982, pp. 329-334. (6 pages) Cited by 8 patents
  • Craig S. Walker, et al., "The T-superfamily of Conotoxins", The Journal of Biological Chemistry, vol. 274, No. 43, Oct. 22, 1999, pp. 30664-30671. (8 pages) Cited by 3 patents [ISI abstract]
  • Baldomero M. Olivera, et al., "Generating molecular diversity in Conus venoms", Abstract.
  • Alan C. Rigby, et al. "A conotoxin from Conus textile with unusual posttranslational modifications reduces presynaptic Ca2+ influx", Proc. Natl. Acad. Sci. USA, vol. 96, May 1999, pp. 5758-5763. (6 pages) Cited by 3 patents [ISI abstract]
  • Internal Scientific Report, Metabolic Stability of CGX-1079 (α-Conopeptide Gl), May 4, 2000.
  • Alan C. Rigby, et al., "Gamma-carboxyglutamic acid-containing conotoxins in the venom from Conus textile", Abstract.
  • Problem Solving Report Question No.-1026746.044, Neurex--Conotoxin, Calcium Channel Patents, May 2, 2000, Tech.Spec.--John Leavitt.


    • Continuity Data:
    Application Number Filed Notes
    US2000000488799 2000-01-21  is a related to the prior publication
         US20030050435A1 issued 2003-03-13  Alpha-conotoxin peptides
    US2006000482148 2006-07-07  is a continuation of
    US2004000839179  2004-05-06   (abandoned)
         US20040204362A1 issued 2004-10-14   Alpha-conotoxin peptides
    US2004000839179 2004-05-06  is a division of
    US2001000908741  2001-07-20   (pending) [presumed granted]
         US6855805 issued 2005-02-15   α-conotoxin peptides
    US2004000839179 2004-05-06  is a division of
    US2001000908741  2001-07-20   (granted)
         US6855805 issued 2005-02-15   α-conotoxin peptides
    US2001000908741   is a continuation in part of
    US2001000488799  2001-01-21
         US6268473 issued 2001-07-31   α-conotoxin peptides
    US2001000908741 2001-07-20  is a continuation in part of
    >US2000000488799<  2000-01-21   (granted)
         US6268473 issued 2001-07-31   α-conotoxin peptides
    US2001000908741 2001-07-20  is a continuation in part of
    >US2000000488799<  2000-01-21   (patented) [presumed granted]
         US6268473 issued 2001-07-31   α-conotoxin peptides
    US2000000488799 2000-01-21  is a non-provisional of provisional
    US2000000221557P  2000-07-28
    US2000000488799 2000-01-21  is a non-provisional of provisional
    US2000000219407P  2000-07-20
    US2000000488799 2000-01-21  is a non-provisional of provisional
    US1999000116882P  1999-01-22
    US2000000488799 2000-01-21  is a non-provisional of provisional
    US1999000116881P  1999-01-22


    Inquire Regarding Licensing

    Powered by Verity
    Plaques from Patent Awards      Gallery of Obscure PatentsNominate this for the Gallery...

    Thomson Reuters Copyright © 1997-2010 Thomson Reuters 
    Subscriptions  |  Web Seminars  |  Privacy  |  Terms & Conditions  |  Site Map  |  Contact Us  |  Help